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X-ray analysisThis paper describes a method for the chemical synthesis of 7a,12a-dihydroxy-4-cholesten-3-one (1a)
and its biological precursor, 7a-hydroxy-4-cholesten-3-one (1b), both of which are key intermediates
in the major pathway of bile acid biosynthesis from cholesterol. The principal reactions involved were
(1) building of the cholesterol (iso-octane) side chain by 3-carbon elongation of the cholane (iso-pentane)
one, (2) oxidation sequence to transform the 3a-hydroxy group of the steroidal A/B-ring to the desired 4-
en-3-one system, and (3) appropriate protection strategy for hydroxy groups in the positions at C-7 and
C-12 in the steroid nucleus. The absolute structure of 1a and 1b were conﬁrmed by NMR and X-ray crys-
tallography. The targeted compounds 1a and 1b, prepared in 11 steps from 2a and 2b respectively, should
be useful for biochemical studies of bile acid biosynthesis or clinical studies of bile acid metabolism, as
plasma levels of 1b (also termed C4) have been shown to correlate highly with the rate of bile acid bio-
synthesis in man.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Bile acids are synthesized by the liver from cholesterol by a
complex series of reactions involving at least 14 enzymatic steps
[1a,1b]. In humans, a failure of any of these enzymatic reactions
will result in accumulation of intermediates in the bile acid biosyn-
thesis pathway, as well as a deﬁciency in the normal primary bile
acids, cholic acid (CA; 2a) and chenodeoxycholic acid (CDCA; 2b).
Defective bile acid biosynthesis presents clinically as liver disease
in infants and may be fatal unless treated by bile acid replacement
therapy; such therapy is life-saving [2,3].
As shown in Fig. 1, the initial biosynthetic transformation of
cholesterol to the primary bile acids (2a and 2b) involvessequential 7a-hydroxylation (catalyzed by cholesterol 7a-hydrox-
ylase, Cyp7A1) followed by C-3 oxidation and concomitant double
bond migration (catalyzed by a C27 3b-hydroxy-D5-C27-steroid oxi-
doreductase, HSD3B7) to form 7a-hydroxy-4-cholesten-3-one (1b),
which is a precursor of CDCA (2b) [1c]. The transformation of 1a
catalyzed by the microsomal steroid 12a-hydroxylase Cyp8b1
leads to the formation of 7a,12a-dihydroxy-4-cholesten-3-one
(1a), which is ultimately converted to CA (2a) [1d].
The two unsaturated oxysterols (1a and 1b) are thus pivotal
biosynthetic intermediates in the so-called ‘‘neutral’’ pathway of
primary bile acid biosynthesis and are of sustained interest in
the biosynthetic, biological, physiological, and metabolic studies
of bile acids [3]. In addition, the plasma level of 1b has been shown
to correlate highly with the rate of bile acid biosynthesis [4], and is
thus a useful non-invasive biomarker for detecting increased bile
acid biosynthesis. Such a determination is useful in patients with
idiopathic diarrhea to determine whether bile acid malabsorption
is present, as the compensatory increase in bile acid synthesis
may lead to chronic diarrhea, because of bile acid induced secre-
tion in the large intestine [5].
For the accurate analysis of 1a and 1b in plasma, authentic
reference compounds are needed. Although 1b is available from
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Fig. 1. Major biosynthetic pathway from cholesterol of the two primary bile acids in man – CA (2a) and CDCA (2b).
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To our knowledge, however, the chemical synthesis of 1a and 1b,
which have aD4-3-oxo-7a-hydroxy structure in the steroid nucleus
and the iso-octane (cholestane) side chain at the C-17 position, has
not yet been reported. During the course of our studies on bile acid
metabolism in vertebrates, we required 1a and 1b as authentic ref-
erence standards. We report here the chemical synthesis of 1a and
1b using inexpensive reagents and readily available steroid sources.
Very recently, Björkhem have reviewed his ﬁve decades with oxys-
terols, particularly for 1b [Biochimie 2013;95:448-54].
2. Results and discussion
2.1. Enzymatic synthesis
Alexander and Fisher reported some years ago a convenient
enzymatic synthesis of 7a-hydroxy-4-cholesten-3-one (1b) by the
hydroxypropyl-b-cyclodextrin-facilitated cholesterol oxidase oxi-
dation of 5-cholestene-3b,7a-diol (7a-hydroxycholesterol) [6]. In
this enzymatic synthesis using cholesterol oxidase (from Brevibacte-
rium sp.) and catalase, there is a simultaneous oxidation of the
3b-hydroxy group to the 3-oxo group and migration of the double
bond from D5 to D4; this procedure has been used for thepreparation of D4-3-oxo-7a-hydroxy steroids [7]. In preliminary
work, we developed an improved enzymatic method for the prepa-
rationof1b and its 7b-isomer, by the route shown in Fig. 2. However,
such an enzymatic synthesis is expensive, does not yield a pure
product, and is useful only on a micromolar scale. Furthermore, a
major shortcoming of this enzymatic synthesis is its inability to gen-
erate 7a,12a-dihydroxy-4-cholesten-3-one (1a), themetabolic pre-
cursor of cholic acid, a major primary bile acid in vertebrates.
Thus, we described herein an alternative, non-enzymatic chem-
ical preparation of 1a and 1b, starting from easily available com-
mercial materials.
2.2. Chemical synthesis
Wereportheresynthesis of1a, the target compound, from2a in11
steps, according to the route shown in Fig. 3. The principal steps con-
sisted of (1) the elongation (by three carbon atoms) of the C5 cholane
(iso-pentane) side-chain in 2a to the C8 cholestane (iso-octane) side
chain inﬁve steps and (2) the transformationof theA/B-ring structure
into the 3-oxo-D4-7a,12a-dihydroxy steroid nucleus in six steps.
Our initial effort was directed to the construction of the choles-
tane side-chain from 2a. Reduction of the terminal carboxyl group
to the corresponding primary alcohol is usually carried out with
AcO AcO
OHO OH OH
1b
O
H H
H
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Reagents and conditions: (i) hydropropyl-β-cyclodextrin/ cholesterol oxidase/ catalase/ phosphate
buffer pH 7/H2O, at 20 oC for 24 h.
Fig. 2. Enzymatic synthesis of 1b from cholesterol.
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Reagents and conditions: (a) acetic anhydride/ 4-dimethylaminopyridine/ pyridine, at 40 oC for 1 h. (b) NaBH4/ Et3N/ ethyl
chloroformate/ THF, at 0 oC for 2 h. (c) 2,2,6,6-tetramethylpiperidine 1-oxyl free radical/ KBr/ NaOCl aq./ Na2CO3 aq./
NaHCO3 aq. buffer (pH 8.6), at 0 oC for 20 min. (d) isopropyltriphenylphosphonium iodide/ 1.6M n-BuLi in hexane/ THF,
at 0 oC for 30 min, then tris[2-(2-methoxyethoxy)ethyl]amine/ THF, at 0 oC for 15 min. (e) H2/ 10% Pd/C/ MeOH:AcOH:
EtOAc (10:10:1), at r.t. for 3 h. (f) HCl/ MeOH, at 30 oC for 6 h. (g) CrO3/ H2SO4/ acetone/ CH2Cl2, at 0 o C for 30 min.
(h) 10% KOH/ MeOH, at r.t. 16 h. (i) HCOOH/ HClO4, at r.t. for 1 h. (j) IBX/ trif luoroacetic acid/ DMSO, at 40 oC for 40 h.
(k) 0.2N NaOH aq., at r.t. 30 min.
Fig. 3. Synthetic route to the target compounds (1a and 1b) from bile acids (2a and 2b).
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930 S. Ogawa et al. / Steroids 78 (2013) 927–937LiAlH4 under strong alkaline conditions. However, this reduction
technique has a disadvantage, as it also causes partial or complete
hydrolysis of the acetyl protecting groups at C-3, C-7 and C-12 in
3a. Therefore, we explored the use of less basic NaBH4, combined
with ethyl chloroformate and triethylamine (Et3N) [8]. Thus, CA
peracetate, 3a, prepared from 2a by the usual method, was treated
with NaBH4/ethyl chloroformate/Et3N in dry THF to give the corre-
sponding 24-hydroxy-3a,7a,12a-triacetate 4a. As expected, the
reduction reaction proceeded smoothly via the anhydride deriva-
tive of 3a as an intermediate without hydrolysis of the acetyl
groups.
Preliminary experiments revealed that the conversion of 4a to
the corresponding 3a,7a,12a-triacetoxy-24-aldehyde (5a) by the
use of pyridinium chlorochromate (PCC) and pyridinium dichro-
mate (PDC) as oxidants was unsatisfactory; the yield was less than
60% and required tedious puriﬁcation of the desired product by
chromatography. However, when 4a was subjected to oxidation
with sodium hypochlorite (NaClOnH2O) in the presence of cata-
lytic amounts of 2,2,6,6-tetramethylpiperidine1-oxyl (as free radi-
cal; TEMPO) in a NaHCO3 buffer solution [9], mild, selective
oxidation of the C-24 primary alcohol 4a took place, to afford the
corresponding C-24 aldehyde 5a in good isolated yield of 79%.
Subsequent Wittig reaction of 5a with isopropylphenylphos-
phonium iodide in the presence of n-BuLi at 0 C for 15 min,
yielded the unsaturated D24-3,7,12-triacetate 6a having the C8
branched side chain. Although the basic conditions resulted con-
currently in partial or complete deprotection of the acetyl groups
at C-7 and C-12 in 6a, these mixtures were re-acetylated without
difﬁculty. Catalytic hydrogenation of 6a using 10% Palladium on
carbon (Pd/C) catalyst in a solvent mixture of EtOAc–methanol–
acetic acid under slightly positive pressure proceeded smoothly
to afford 5b-cholestan-3a,7a,12a-triacetate (7a) exclusively. Thus,
the elongation of the C5 side chain by three carbon atoms to form
the C8 cholestane side chain was accomplished in 5 steps from 2a;
the total yield of 7a from 2a was ca. 40%.
The C27 triacetate 7a, when treated with methanolic HCl at
30 C, was deprotected regioselectively at the equatorially-ori-
ented 3a-acetyl group to yield 7a,12a-diacetoxy-5b-cholestan-
3a-ol (8a), Subsequent oxidation of 8a with Jones reagent, fol-
lowed by complete alkaline hydrolysis (using 10% methanolic
KOH) of the resulting 3-oxo-7a,12a-diacetoxy derivative (9a) pro-
ceeded cleanly to give 7a,12a-dihydroxy-5b-cholestan-3-one
(10a) nearly quantitatively.
The choice of a suitable protecting group for the 7a- and 12a-
hydroxy groups in 10a was an essential factor for subsequent
reactions. In our exploratory works, attempted dehydrogenation
of 9a with IBX (see below) was successful, but subsequent hydro-
lysis of the resulting 7a,12a-diacetoxy-4-cholesten-3-one failed.
Under the various alkaline hydrolysis conditions that were exam-
ined, allylic elimination of the 7a-acetyl group took place to give
a mixture of 12a-hydroxy-4,6-cholestadien-3-one and 12a-acet-
oxy-4,6-cholestadien-3-one as the major products. To prevent
the elimination, we protected the 7a- and 12a-hydroxy groups
as formate derivatives. The diformyloxy-5b-cholestan-3-one
(11a) was found to be preferable to 9a as a substrate for the
IBX reaction, because the formate is more labile and the deprotec-
tion is much easy under mild conditions. The compound 11a was
prepared nearly quantitatively from 10a by the usual formic acid/
HClO4 method [10].
Our preliminary experiments revealed that dehydrogenation of
11a with iodoxybenzene catalyzed by benzeneselenic anhydride
was successful [10], but that selective hydrogenation of the D1-
bond of the resulting 7a,12a-diformyloxy-1,4-choladien-3-one
was unsuccessful. An attempt at direct oxidation of 11a with sele-
nium dioxide [11] to give 7a,12a-diformyloxy-4-cholesten-3-one
(12a) also failed.Recently the report of a new, powerful dehydrogenation oxi-
dant, o-iodoxybenzoic acid (IBX), prompted us to apply this re-
agent for the preparation of the targeted 12a from 11a. Nicolaou
et al. [12] have reported that IBX, a readily available hypervalent
iodine (V) reagent, oxidizes ketones efﬁciently to the conjugated
enones or dienones, and benzylamines to the amines. In addition,
IBX was found to be highly effective in mediating dehydrogena-
tions adjacent to carbonyl functionalities (to form a,b-unsaturated
carbonyl compounds) as well as at benzylic and related carbon
centers (to form conjugated aromatic carbonyl systems). In the
IBX-mediated dehydration, some 3-oxo-5a-steroids (trans A/B-ring
juncture) have been shown to be converted to the corresponding 3-
oxo-D1 enones or 3-oxo-D1,4 dienones, depending on the experi-
mental conditions. However, Li and Tochtrop [13] have recently re-
ported that IBX smoothly and regioselectively performs the
dehydrogenation of 3-oxo-5b-steroids (cis A/B-ring juncture) to
give the 3-oxo-D4 enones, probably owing to the stereochemical
difference of the A/B-rings in the steroid nucleus.
When 11awas treated with freshly prepared IBX (see Section 3)
[14] in DMSO containing triﬂuoroacetic acid at 40 C for 40 h, the
dehydrogenation reaction took place as expected at the hydrogen
atoms attached to C-4 and C-5 to give the desired a,b-unsaturated
ketone, 7a,12a-diformyloxy-4-cholesten-3-one (12a), in moderate
yield (50%), without being accompanied by the elimination of the
7a-formyl group. Also, the undesirable products – 3-oxo-D1-
7,12-diformate and 3-oxo-D1,4-7,12-diformate – as well as the
other by-products, were not formed at all. Based on a suggestion
of Nicolaou et al. [12], a possible ionic-mechanism for the dehydro-
genation of 11a by IBX suggests that the reaction is initiated by sin-
gle electron transfer from the substrate 11a to IBX to form a radical
cation which reacts further to give the desired 12a.
We found that the use of commercially available stabilized IBX
(SIBX), which contains 55 wt.% of 2-iodobenzoic acid as a stabilizer,
was unsatisfactory, because it lacked reproducibility, and often re-
sulted in a complicated mixture of products. Isolation of 12a was
tedious and time-consuming, and as a result, was obtained in
low yield.
In the ﬁnal step, the usual alkaline hydrolysis of 12a with aque-
ous NaOH at room temperature for 30 min gave the targeted
7a,12a-dihydroxy-4-cholesten-3-one (1a). In this hydrolysis reac-
tion of 12a, the elimination product – 3-oxo-4,6-diene – was pro-
duced (2%). On the other hands, when 12b was treated with
aqueous NaOH, 3-oxo-4,6-diene was detected 2% as by-product
(yields were established by HPLC). Thus, our successful strategy
for obtaining the desired changes in the steroid nucleus was based
on solving two problems – ﬁrst was selection of the appropriate
protecting groups for the hydroxy groups of 2a and 2b and the sec-
ond was the use of a modiﬁed IBX as the dehydrogenation reagent.
Analogous 7a-hydroxy-4-cholesten-3-one (1b) (lacking a 12a-hy-
droxy group) was also prepared starting from CDCA (2b) by essen-
tially the same procedures as described in detail for the
preparation of 1a from 2a. Overall yields of 1a and 1b in 11 steps
were ca. 6.5% and 7.4%, respectively.
2.3. NMR properties
In the 1H-NMR spectrum of 1a, a pair of doublets appearing at
0.86 and 0.87 ppm were assigned to the three protons at C-26
and C-27 in the terminal isopropyl methyl groups, providing evi-
dence for the structure of the C8 cholestane side-chain. The 19-
H3 signal (singlet) in 1a was appreciably shifted downﬁeld by
0.19 ppm and resonated at 1.19 ppm, compared to that in 10a
(1.00 ppm), whereas a signal appearing at 5.82 ppm as a singlet
was assigned to the 4-H. These observations indicated that 1a
has the 3-oxo-D 4-7a-hydroxy structure in the A/B-ring juncture
[15]. Furthermore, the occurrence of the two quaternary 13C signals
Table 3
Selected bond lengths (Å) and angles () for 1b.
O1-C3 1.222(4) O1-C3-C2 121.6(3)
C3-C4 1.440(4) O1-C3-C4 121.6(3)
C4-C5 1.336(4) C2-C3-C4 116.8(3)
C5-C6 1.491(4) C3-C4-C5 123.6(3)
C6-C7 1.531(4) C3-C4-H6 118.3
C7-C8 1.521(4) C5-C4-H6 118.1
C7-O2 1.426(4) C4-C5-C6 120.2(3)
O2-H1 0.840 C5-C6-C7 111.3(3)
C6-C7-C8 108.9(2)
C6-C7-O2 108.0(2)
C7-O2-H1 109.5
Table 2
Atomic coordinates for 1b.
Atom x y z
O1 0.3802(4) 0.59455(13) 0.24964(10)
O2 0.4221(3) 0.24336(10) 0.28138(7)
C1 0.1216(5) 0.47800(13) 0.34909(10)
C2 0.1304(6) 0.55708(15) 0.31535(12)
C3 0.2649(5) 0.53955(17) 0.26951(13)
C4 0.2480(5) 0.45526(15) 0.24879(11)
C5 0.1334(4) 0.39204(15) 0.27063(10)
C6 0.0990(6) 0.31000(15) 0.24375(10)
C7 0.1829(5) 0.23469(15) 0.27502(9)
C8 0.0593(4) 0.23467(13) 0.32505(8)
C9 0.0939(4) 0.31865(12) 0.35279(8)
C10 0.0296(4) 0.39988(14) 0.32228(10)
C11 0.0210(5) 0.31593(15) 0.40415(10)
C12 0.0523(5) 0.23932(13) 0.43621(9)
C13 0.0132(4) 0.15567(13) 0.40896(9)
C14 0.1386(4) 0.16165(12) 0.35876(8)
C15 0.1387(6) 0.07132(13) 0.33866(10)
C16 0.1649(5) 0.01642(15) 0.38624(9)
C17 0.1299(4) 0.07567(12) 0.43173(8)
C18 0.2409(4) 0.13839(17) 0.40204(11)
C19 0.2306(4) 0.40816(17) 0.31629(12)
C20 0.0231(4) 0.03032(13) 0.47663(9)
C21 0.0243(6) 0.08980(17) 0.52038(10)
C22 0.1677(5) 0.04384(15) 0.49369(9)
C23 0.0704(5) 0.09800(16) 0.53488(10)
C24 0.1985(6) 0.17933(17) 0.54577(11)
C25 0.1081(9) 0.2340(3) 0.58762(14)
C261 0.1332(15) 0.1910(4) 0.6351(3) 0.6(occ.)
C262 0.097(2) 0.2454(6) 0.5982(4) 0.4(occ.)
C27 0.2296(11) 0.3163(3) 0.59058(15)
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the 13C-NMR spectrum of 1a also indicated the presence of the con-
jugated enone moiety. The 2D HMBC spectrum of 1a showed the
correlation peaks between 19-H3 vs C-5 and 4-H vs C-5, strongly
indicating the presence of the D4-bond.
Essentially identical 1H- and 13C-NMR characteristics were ob-
served in the spectra of 1b.
2.4. X-ray analysis of 1b
The molecular structure of 7a-hydroxy-4-cholesten-3-one (1b)
was determined by X-ray analysis. Data for crystallographic de-
tails, atomic coordinates, and selected bond lengths (Å) and angles
() for 1b are presented in Tables 1–3, respectively. Thus, 1b crys-
tallizes in a P212121 space group having four molecules to the unit
cell. The molecular structure and the crystal structure of 1b are
presented in Figs. 4 and 5, respectively. The bond distances and
bond angles have the expected values for this kind of steroid. In
particular, the enone O@C–C@C fragment in ring A is almost
anti-periplanar with a small dihedral angle of 3.55 (see Table 3).
The bond distances are 1.222(4) for O1-C3, 1.440(4) for C3-C4,
and 1.336(4) Å for C4–C5, respectively.
The X-ray crystal structure of 1b reveals that it is aligned as a
zigzag array connected by intermolecular hydrogen bonds be-
tween the oxygen atom at C-3 (O1) and the hydroxy-group (O2)
of the neighboring molecule along the b axis with an O1O2 dis-
tance of 2.743(3) Å. These arrays are arranged in a head-to-tail
manner, and form a molecular layer parallel to the bc-plane. Also
shown in Fig. 5, the rigid steroid rings create a large free space into
which the side chain is located. Furthermore, because of the ab-
sence of strong intermolecular interactions, the C8 alkyl (choles-
tane) side chain is quite ﬂexible and, therefore, the thermal
motion in that part of the molecule is large. As a consequence, C-
26, C-27 and the methine hydrogen atom at the terminal isopropyl
group are disordered mutually over three positions due to the free
rotation around the C-24–C-25 bond. As a result of the reﬁne-
ments, the site occupancy factor of C-27 was almost 1.0, and C-
26 was divided in C-26-1 and C-26-2 with site occupancy factors
of 0.60 and 0.40, respectively. The methine hydrogen atom of the
isopropyl group was not included in the reﬁnement process. Thus,
X-ray analysis provided conclusive evidence for the stereochemical
structure of 1b, resolving the A/B-ring juncture in the steroid nu-
cleus and the terminal isopropyl group at the C8 cholestane
side-chain.Table 1
Crystallographic details for 1b.
1b
Formula C27H44O2
M 400.64
Crystal system Orthorhombic
Space group P212121
a (Å) 5.893(1)
b (Å) 15.734(3)
c (Å) 26.699(6)
V (Å3) 2475.6(9)
Z value 4
Dc/g cm3 1.075
F(000) 888
l (Mo Ka)/cm1 0.650
No. reﬂns measured 29,147
No. unique reﬂns. 5678
No. observed (I > 3r) 3249
R1 (I > 3r) 0.049
wR2 (I > 3r) 0.059
Goodness of ﬁt 0.943
Fig. 4. The molecular structure of 1b with numbered atoms. Thermal ellipsoids are
drawn at 30% of probability.In conclusion, we report herein the chemical synthesis of 1a and
1b from 2a and 2b, respectively. The synthesis proceeded through
easily prepared, well deﬁned intermediates and provided analyti-
cally pure products. The availability of 1a and 1b will permit fur-
ther studies on their plasma levels and facilitate studies on the
mechanism by which 1b (and possibly 1a) enters plasma, presum-
ably as a component of secreted lipoproteins. It will be of interest
to determine whether plasma levels of 1a also correlate with the
rate of bile acid synthesis, and if so, which intermediate (1a or
Fig. 5. Crystal structure of 1b viewed along the a axis.
932 S. Ogawa et al. / Steroids 78 (2013) 927–9371b) shows a better correlation. In addition, the compounds are now
available as substrates for ensuing biosynthetic transformations
catalyzed by 12a-hydroxylase (acting on 1b) as well as the D4-3-
oxosteroid 5b-reductase (acting on both 1a and 1b) [16].3. Experimental
3.1. Materials
CA (2a) was obtained from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan). CDCA (2b) was supplied from Mitsubishi Tanabe
Pharma Co. (Tokyo, Japan). All other chemicals and solvents were
of analytical reagent grade and available from commercial sources.
All compounds were dried by azeotropic distillation prior to use.3.2. Instruments
All melting points (mp) were determined on a micro hot stage
apparatus and are uncorrected. 1H- and 13C-NMR spectra were ob-
tained on a JEOL ECA 500 FT instrument operated at 500 and
125.8 MHz, respectively, with CDCl3 or CD3OD containing 0.1%
Me4Si as the solvent, except where otherwise indicated; chemical
shifts were expressed in d (ppm) relative to Me4Si. The 13C distor-
tionless enhancement by polarization transfer (DEPT; 135, 90,
and 45) spectra were measured to determine the exact 13C signal
multiplicity and to differentiate between CH3, CH2, CH, and C based
on their proton environments. In order to further conﬁrm the 1H
and 13C signal assignments for some of compounds, two-dimensional (2D) 1H detected heteronuclear multiple quantum
(HMQC; 1H-13C coupling) and 1H detected heteronuclear multiple
bond correlation (HMBC; long-range 1H-13C coupling) experiments
were also performed.
High-resolution mass spectra by electrospray ionization
(HR-ESI-MS) or by atmospheric pressure chemical ionization
(HR-APCI-MS) were carried out using a JEOL AccuTOF JMS-
T100LC liquid chromatography-mass spectrometer equipped with
an ESI source or an APCI source and coupled to a Agilent 1200 ser-
ies binary pump (Agilent Technologies Inc., Santa Clara, CA, USA)
operated in the negative ion mode or positive ion mode.
High-performance liquid chromatography (HPLC) was ob-
tained a Jasco LC-2000 plus HPLC system, consisting of two
PU-2085 high-pressure pumps, a MX-2080–32 solvent mixing
module, and a CO-2060 column heater equipped with a Chrom-
NAV data processing system (Tokyo, Japan). The column was a
Capcell Pack type AQ C18 (particle size, 3 lm, 250 mm  3.0 mm
I.D.; Shiseido, Tokyo, Japan) kept at 37 C. The detector was an
Alltech 2000ES evaporative light-scattering detector (Deerﬁeld,
IL, USA) operated under the following conditions: the ﬂow rate
of puriﬁed compressed air used as a nebulizing gas was 1.8 L/
min, and the temperature of the heated drift was 68.3 C (1a)
or 65.5 C (1b). The mobile phase used was a mixture of
15 mM-ammonium acetate/acetic acid buffer solution (pH 5.4)
and methanol [15:85 (1a) or 1:9 (1b), v/v]; the ﬂow rate was
kept at 0.4 lL/min during the analysis. Analytical thin-layer
chromatography (TLC) was performed on pre-coated silica gel
plates (E. Merck, Darmstad, Germany) using EtOAc–hexane mix-
tures as the developing solvent.
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3.3.1. 2-Iodoxybenzoic acid (IBX)
IBX was prepared, according to the following procedure [14]. In
short, to a solution of 2-iodobenzene (1.0 g, 4 mmol) in water
(13 mL) was added OXONE (monopersulfate compound; 2KHSO5/
KHSO4/K2SO4; 3.62 g, 5.8 mmol). The resulting suspension was
stirred at 70 C for 3.5 h and then at 5 C for 1.5 h. The precipitated
semi-crystalline solid was ﬁltered, washed with water and acetone,
and dried at room temperature for 16 h to afford IBX, which was
directly used without further puriﬁcation. ‘‘Caution! IBX is explo-
sive at high temperature.’’
3.3.2. 3a,7a,12a-Triacetoxy-5b-cholan-24-ol (4a)
A mixture of CA peracetate 3a (11.8 g, 22.1 mmol), Et3N (4 mL,
28.7 mmol) in dry THF (100 mL), and ethyl chloroformate
(2.8 mL, 29.4 mmol) was stirred at room temperature for 2 h. To
the resulting milky turbid suspension, NaBH4 (4.0 g, 106 mmol)
and then methanol (10 mL) were added gradually with ice-bath
cooling, until a clear solution was obtained. After further stirring
at 0 C for 2 h, the reaction product was extracted with EtOAc.
The combined extract was washed with saturated brine, dried over
Drierite, and evaporated to dryness. The oily residue was
chromatographed on a silica gel column (250 g). Elution with hex-
ane–EtOAc (7:3, v/v) afforded the corresponding 24-hydroxy-
3,7,12-triacetate 4a which was recrystallized from Et2O–hexane
as colorless thin plates; yield, 6.9 g (60%); mp, 134–135 C. 1H-
NMR (500 MHz, CDCl3): d = 0.74 (s, 3H, 18-H3), 0.84 (d, 3H,
J = 6.3 Hz, 21-H3), 0.93 (s, 3H, 19-H3), 2.05, 2.09, 2.14 (each s, 3H,
OCOCH3), 3.60 (m, 2H, 24-H2), 4.56 (m, 1H, 3b-H), 4.91 (brs, 1H,
7b-H), 5.10 (brs, 1H, 12b-H). 13C-NMR (125.8 MHz, CDCl3):
d = 12.1 (C-18), 17.7 (C-21), 21.3, 21.4, 21.5 (each OCOCH3), 22.4
(C-19), 22.7 (C-15), 25.4 (C-11), 26.8 (C-2), 27.1 (C-16), 28.8 (C-
9), 29.0 (C-22), 31.1 (C-6), 31.5 (C-23), 34.2 (C-10), 34.5 (C-4),
34.6 (C-1), 34.7 (C-20), 37.6 (C-8), 40.8 (C-5), 43.3 (C-14), 44.9
(C-13), 47.4 (C-17), 63.2 (C-24), 70.6 (C-7), 74.0 (C-3), 75.4 (C-
12), 170.3, 170.5, 170.5 (each OCOCH3). HR-ESI-MS, calcd. for
C30H49O7 [M + H]+, 521.3478; found 521.3431.
3.3.3. 3a,7a-Diacetoxy-5b-cholan-24-ol (4b)
The C-24 carboxyl group of CDCA diacetate 3b (12.0 g,
25 mmol) [obtained from CDCA (2b)], was reduced by the proce-
dure described for the preparation of 4a to give 24-hydroxy-3,
7-diacetate 4b, which was recrystallized from Et2O-hexane as col-
orless thin plates; yield, 6.9 g (59%); mp, 160–162 C (literature va-
lue: mp, 159 C) [17]. 1H-NMR (500 MHz, CDCl3): = d 0.65 (s, 3H,
18-H3), 0.93 (s, 3H, 19-H3), 0.94 (d, 3H, J = 5.2 Hz, 21-H3), 2.05,
2.09 (each s, 3H, OCOCH3), 3.61 (m, 2H, 24-H2), 4.59 (m, 1H, 3b-
H), 4.88 (brs, 1H, 7b-H). 13C-NMR (125.8 MHz, CDCl3): d = 11.7
(C-18), 18.5 (C-21), 20.6 (C-11), 21.4, 21.6 (each OCOCH3), 22.6
(C-19), 23.5 (C-15), 26.7 (C-2), 28.1 (C-16), 29.2 (C-23), 31.4 (C-
6), 31.7 (C-22), 34.0 (C-10), 34.7 (C-8), 34.8 (C-4), 34.9 (C-1), 35.4
(C-20), 37.9 (C-9), 39.5 (C-12), 40.9 (C-5), 42.6 (C-13), 50.4 (C-
14), 55.9 (C-17), 63.5 (C-24), 71.2 (C-7), 74.2 (C-3), 170.5, 170.6
(OCOCH3). HR-APCI-MS, calcd. for C28H47O5 [M + H]+, 463.3424;
found 463.3439.
3.3.4. 3a,7a,12a-Triacetoxy-5b-cholan-24-al (5a)
To a solution of the 24-hydroxy-3,7,12-triacetate 4a (1.0 g,
1.9 mmol) in CH2Cl2 (50 mL), 2,2,6,6-tetramethylpiperidine1-oxyl
free radical (TEMPO) (7 mg, 45 lmol), and KBr (24 mg) were added
gradually with ice-bath cooling. To the mixture, a solution of NaO-
Cl (2 mL) dissolved in a buffer solution (pH 8.6, 14 mL) prepared
from 0.5 M sodium bicarbonate, and 0.05 M sodium carbonate
was added. The mixture was stirred at 0 C for 20 min; the reaction
was monitored by TLC using hexane–EtOAc (1:1, v/v) as thedeveloping solvent. After adding methanol (1 mL), the reaction
product was extracted with CH2Cl2. The combined extract was
washed with water, dried over Drierite, and evaporated to dryness
to give the crude 24-aldehyde-3,7,12-triacetate 5a. Recrystalliza-
tion from methanol afforded the analytically pure 5a as colorless
thin plates; yield, 790 mg (80%); mp, 86–87 C (literature value:
mp, 55 C) [18]. 1H-NMR (500 MHz, CDCl3): d = 0.73 (s, 3H, 18-
H3), 0.82 (d, 3H, J = 5.4 Hz, 21-H3), 0.92 (s, 3H, 19-H3), 2.05, 2.09,
2.14 (each s, 3H, OCOCH3), 4.58 (m, 1H, 3b-H), 4.91 (brs, 1H, 7b-
H), 5.09 (brs, 1H, 12b-H), 9.76 (s, 1H, 24-CHO). 13C-NMR
(125.8 MHz, CDCl3): d = 12.2 (C-18), 17.6 (C-21), 21.4, 21.5, 21.6
(each OCOCH3), 22.5 (C-19), 22.9 (C-15), 25.7 (C-11), 27.0 (C-2),
27.3 (C-16), 27.7 (C-22), 29.0 (C-9), 31.3 (C-6), 34.2 (C-10), 34.5
(C-4), 34.7 (C-1), 34.4 (C-20), 37.9 (C-8), 40.9 (C-23), 41.0 (C-5),
43.5 (C-14), 45.2 (C-13), 47.5 (C-17), 70.7 (C-7), 74.1 (C-3), 75.3
(C-12), 170.3, 170.5, 170.5 (each OCOCH3), 202.8 (C-24). HR-
ESI-MS, calcd. for C30H47O7 [M + H]+, 519.3322; found 519.3315.
3.3.5. 3a,7a-Diacetoxy-5b-cholan-24-al (5b)
The 24-hydroxy-3,7-diacetate 4b (1.0 g, 2.16 mmol) was con-
verted to the corresponding 24-aldehyde-3,7-diacetate 5b by the
TEMPO oxidation as described for the preparation of 5a. The crude
5b was recrystallized from Et2O as colorless thin plates; yield,
882 mg (89%); mp, 153–155 C (literature value: mp, 153–154 C)
[17]. 1H-NMR (500 MHz, CDCl3): d = 0.63 (s, 3H, 18-H3), 0.92 (d,
3H, J = 6.3 Hz, 21-H3), 0.93 (s, 3H, 19-H3), 2.03, 2.06 (each s, 3H,
OCOCH3), 4.59 (m, 1H, 3b-H), 4.88 (brs, 1H, 7b-H), 9.76 (s, 1H,
24-CHO). 13C-NMR (125.8 MHz, CDCl3): d = 11.7 (C-18), 18.4 (C-
21), 20.6 (C-11), 21.5, 21.6 (each OCOCH3), 22.7 (C-19), 23.5 (C-
15), 26.8 (C-2), 28.0 (C-16), 28.1 (C-22), 31.3 (C-6), 34.1 (C-20),
34.6 (C-10), 34.8 (C-4), 34.9 (C-1), 35.3 (C-9), 37.9 (C-8), 39.5 (C-
12), 40.9 (C-23), 41.0 (C-5), 42.7 (C-13), 50.4 (C-14), 55.8 (C-17),
71.2 (C-7), 74.1 (C-3), 170.4, 170.6 (each OCOCH3), 203.1 (C-24).
HR-APCI-MS, calcd. for C28H45O5 [M + H]+, 461.3267; found
461.3221.
3.3.6. 3a,7a,12a-Triacetoxy-5b-cholest-24-ene (6a)
To a magnetically stirred solution of isopropyltriphenylphos-
phonium iodide (230 mg, 0.53 mmol) in dry THF (5 mL), a solution
of 1.6 M n-BuLi in hexane (330 lL) was added slowly with ice-bath
cooling. The mixture was stirred at 0 C for 30 min. To this mixture,
a solution of the 24-aldehyde-3,7,12-triacetate 5a (100 mg,
0.19 mmol) and tri[2-(2-methoxyethoxy)ethyl]amine (10 lL) dis-
solved in dry THF (5 mL) was then added, and the mixture was fur-
ther stirred at 0 C for 15 min. After quenching the reaction by the
addition of acetone (2 mL), the reaction product was extracted
with CH2Cl2. The combined extract was washed with water, dried
over Drierite, and evaporated to give a light yellow residue. Acety-
lation of the residue by the usual method and subsequent work-up
by solvent extraction gave the crude reaction product. Chromatog-
raphy of the product on a column of silica gel (5 g) and elution with
hexane–EtOAc (4:1, v/v) afforded the desired D24-3,7,12-triacetate
6a which recrystallized from methanol as colorless needles; yield,
63 mg (60%); mp, 84–86 C. 1H-NMR (500 MHz, CDCl3): d = 0.73 (s,
3H, 18-H3), 0.82 (d, 3H, J = 8.1 Hz, 21-H3), 0.92 (s, 3H, 19-H3), 1.59
(s, 3H, 26-H3), 1.68 (s, 3H, 27-H3), 2.05, 2.09, 2.14 (each s, 3H,
OCOCH3), 4.58 (m, 1H, 3b-H), 4.92 (brs, 1H, 7b-H), 5.07 (t, 1H,
J = 3.4 Hz, 24-H), 5.10 (brs, 1H, 12b-H). 13C-NMR (125.8 MHz,
CDCl3): d = 12.2 (C-18), 17.6 (C-26), 17.8 (C-21), 21.4, 21.4, 21.6
(each OCOCH3), 22.5 (C-19), 22.8 (C-15), 24.6 (C-23), 25.5 (C-11),
25.7 (C-27), 26.8 (C-2), 27.2 (C-16), 28.8 (C-9), 31.2 (C-6), 34.3
(C-10), 34.6 (C-4), 34.7 (C-1), 34.8 (C-20), 35.8 (C-22), 37.7 (C-8),
40.9 (C-5), 43.3 (C-14), 45.0 (C-13), 47.7 (C-17), 70.7 (C-7), 74.1
(C-3), 75.4 (C-12), 124.8 (C-24), 131.1 (C-25), 170.3, 170.5, 170.5
(each OCOCH3). HR-APCI-MS, calcd. for C33H53O6 [M + H]+,
545.3842; found 545.3824.
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The 24-aldehyde-3,7-diacete 5b (900 mg 1.95 mmol), was sub-
jected to the Wittig reaction with isopropyltriphenylphosphonium
iodide and processed as described for the preparation of 6a. The
procedure afforded the D24-3,7-diacetate 6b which crystallized
from methanol as colorless needles; yield, 552 mg (58%); mp,
74–76 C (literature value: mp, 67–69 C) [19]. 1H-NMR
(500 MHz, CDCl3): d = 0.64 (s, 3H, 18-H3), 0.92 (d, 3H, J = 5.0 Hz,
21-H3), 0.93 (s, 3H, 19-H3), 1.60 (s, 3H, 27-H3), 1.68 (s, 3H, 26-
H3), 2.03, 2.05 (each s, 3H, OCOCH3), 4.59 (m, 1H, 3b-H), 4.88
(brs, 1H, 7b-H), 5.09 (m, 1H, 24-H). 13C-NMR (125.8 MHz, CDCl3):
d = 11.6 (C-18), 17.6 (C-26), 18.5 (C-21), 20.5 (C-11), 21.4, 21.5
(each OCOCH3), 22.6 (C-19), 23.5 (C-15), 24.7 (C-23), 25.7 (C-27),
26.7 (C-2), 28.2 (C-16), 31.3 (C-6), 34.0 (C-9), 34.6 (C-4), 34.8 (C-
10), 34.9 (C-1), 35.6 (C-20), 36.1 (C-22), 37.9 (C-8), 39.5 (C-12),
40.9 (C-5), 42.7 (C-13), 50.4 (C-14), 56.1 (C-17), 71.3 (C-7), 74.2
(C-3), 125.1 (C-24), 131.0 (C-25), 170.5, 170.6 (each OCOCH3).
HR-ESI-MS, calcd. for C31H51O4 [M + H]+, 487.3787; found
487.3753.
3.3.8. 3a,7a,12a-Triacetoxy-5b-cholestane (7a)
The D24-3,7,12-triacetate 6a (60 mg, 0.11 mmol) in a mixed sol-
vent (20 mL) of EtOAc-methanol-acetic acid (10:10:1, v/v/v) was
hydrogenated in the presence of 10% Pd/C catalyst (6 mg) under
a slight positive pressure. After stirring at room temperature for
3 h, the catalyst was removed by ﬁltration through Celite, and
the solvent of the mother liquor was evaporated under reduced
pressure to give a pale yellow oil of 5b-cholestane 3,7,12-triacetate
(7a). Although 7a was found to be homogeneous according to TLC,
HPLC, and NMR analyses, it resisted crystallization attempts; yield,
58.8 mg (98%). 1H-NMR (500 MHz, CDCl3): d = 0.72 (s, 3H, 18-H3),
0.79 (d, 3H, J = 6.8 Hz, 21-H3), 0.84 (d, 6H, J = 6.8 Hz, 26-H3 and
27-H3), 0.91 (s, 3H, 19-H3), 2.03, 2.07, 2.12 (each s, 3H, OCOCH3),
4.56 (m, 1H, 3b-H), 4.89 (brs, 1H, 7b-H), 5.09 (brs, 1H, 12b-H).
13C-NMR (125.8 MHz, CDCl3): d = 12.0 (C-18), 17.7 (C-21), 21.2,
21.3, 21.4 (each OCOCH3), 22.4 (C-19 and C-26), 22.6 (C-27), 22.7
(C-23), 23.7 (C-15), 25.4 (C-11), 26.9 (C-2), 27.1 (C-16), 27.8 (C-
25), 28.7 (C-9), 31.1 (C-6), 34.2 (C-10), 34.5 (C-1 and C-4), 34.9
(C-20), 35.8 (C-22), 37.6 (C-8), 39.2 (C-24), 40.8 (C-5), 43.2 (C-
14), 44.8 (C-13), 47.6 (C-17), 70.6 (C-7), 73.9 (C-3), 75.3 (C-12),
170.2, 170.3, 170.3 (each OCOCH3). HR-APCI-MS, cald. for
C33H55O6 [M + H]+, 547.3999; found 547.3988.
3.3.9. 3a,7a-Diacetoxy-5b-cholestane (7b)
Catalytic hydrogenation of D24-3,7-diacetate 6b (100 mg,
0.21 mmol) by the procedure as described for the preparation of
7a gave the 5b-cholestane 3,7-diacetate (7b); yield, 98 mg (98%);
mp, 85–87 C (recrystallized from methanol as colorless thin
plates) (literature value: mp, 83–87 C) [20]. 1H-NMR (500 MHz,
CDCl3): d = 0.64 (s, 3H, 18-H3), 0.87 (d, 6H, J = 6.8 Hz, 26-H3 and
27-H3), 0.92 (d, 3H, J = 5.0 Hz, 21-H3), 0.93 (s, 3H, 19-H3), 2.04,
2.06 (each s, 3H, OCOCH3), 4.59 (m, 1H, 3b-H), 4.88 (brs, 1H, 7b-
H). 13C-NMR (125.8 MHz, CDCl3): d = 11.7 (C-18), 18.6 (C-21),
20.6 (C-11), 21.5, 21.6 (each OCOCH3), 22.5 (C-26), 22.7 (C-19),
22.8 (C-27), 23.6 (C-23), 23.8 (C-15), 26.8 (C-2), 28.0 (C-25), 28.1
(C-16), 31.3 (C-6), 34.0 (C-9), 34.6 (C-4), 34.8 (C-10), 34.9 (C-1),
35.7 (C-20), 36.1 (C-22), 37.9 (C-8), 39.4 (C-12), 39.5 (C-24), 40.9
(C-5), 42.6 (C-13), 50.4 (C-14), 56.2 (C-17), 71.3 (C-7), 74.2 (C-3),
170.4, 170.6 (each OCOCH3). HR-APCI-MS calcd. for C31H53O4
[M + H]+, 489.3944; found 489.3938.
3.3.10. 7a,12a-Diacetoxy-5b-cholestan-3a-ol (8a)
A mixture of the 5b-cholestane 3,7,12-triacetate 7a (500 mg,
0.91 mmol) and conc. HCl (6 drops) in methanol (15 mL) was slow
stirred at 30 C for 6 h. Most of the solvent was evaporated under
reduced pressure, and the reaction product was extracted withEtOAc. The combined extract was washed with saturated brine,
dried over Drierite, and evaporated to dryness. The oily residue
was chromatographed on a column of silica gel (15 g). Elution with
EtOAc-hexane (6:4, v/v) gave the 3-hydroxy-7,12-diacetate 8a,
which was crystallized from methanol as colorless needles; yield,
334 mg (72%); mp, 138–141 C. 1H-NMR (500 MHz, CDCl3):
d = 0.72 (s, 3H, 18-H3), 0.79 (d, 3H, J = 6.3 Hz, 21-H3), 0.86 (d, 6H,
J = 6.8 Hz, 26-H3 and 27-H3), 0.91 (s, 3H, 19-H3), 2.09, 2.13 (each
s, 3H, OCOCH3), 3.50 (m, 1H, 3b-H), 4.90 (brs, 1H, 7b-H), 5.10
(brs, 1H, 12b-H). 13C-NMR (125.8 MHz, CDCl3): d = 12.2 (C-18),
17.8 (C-21), 21.4, 21.6 (each OCOCH3), 22.5 (C-19 and C-26), 22.8
(C-23 and C-27), 23.8 (C-15), 25.5 (C-11), 27.3 (C-16), 28.0 (C-
25), 28.9 (C-9), 30.4 (C-2), 31.3 (C-6), 34.3 (C-10), 34.8 (C-1), 35.1
(C-20), 35.9 (C-22), 37.7 (C-8), 38.6 (C-4), 39.4 (C-24), 41.0 (C-5),
43.3 (C-14), 45.0 (C-13), 47.7 (C-17), 70.9 (C-7), 71.7 (C-3), 75.6
(C-12), 170.6, 170.7 (each OCOCH3). HR-APCI-MS calcd. for
C31H51O5 [MH], 503.3737; found, 503.3741.
3.3.11. 7a-Acetoxy-5b-cholestan-3a-ol (8b)
3-Hydroxy-7-acetate 8b was prepared from the 5b-cholestane
3,7-diacetate 7b (600 mg, 1.23 mmol) by selective hydrolysis at
C-3 using concentrated HCl as described for the preparation of
8a. Crystallization of the crude product from EtOAc gave colorless
needles; yield, 437 mg (80%); mp, 145–146 C. 1H-NMR (500 MHz,
CDCl3): d = 0.64 (s, 3H, 18-H3), 0.87 (d, 6H, J = 6.8 Hz, 26-H3 and 27-
H3), 0.92 (d, 3H, J = 5.0 Hz, 21-H3), 0.93 (s, 3H, 19-H3), 2.05 (s, 3H,
OCOCH3), 3.50 (m, 1H, 3b-H), 4.88 (brs, 1H, 7b-H). 13C-NMR
(125.8 MHz, CDCl3): d = 11.6 (C-18), 18.6 (C-21), 20.6 (C-11), 21.6
(OCOCH3), 22.5 (C-26), 22.7 (C-19), 22.8 (C-27), 23.6 (C-23), 23.8
(C-15), 28.0 (C-16), 28.1 (C-25), 30.6 (C-2), 31.4 (C-6), 34.1 (C-9),
34.7 (C-10), 35.2 (C-1), 35.7 (C-20), 36.1 (C-22), 37.9 (C-8), 38.9
(C-4), 39.4 (C-12), 39.5 (C-24), 41.1 (C-5), 42.6 (C-13), 50.4 (C-
14), 56.1 (C-17), 71.4 (C-7), 71.8 (C-3), 170.7 (OCOCH3). HR-ESI-
MS, calcd. for C29H49O3 [MH], 445.3682; found, 445.3647.
3.3.12. 7a,12a-Diacetoxy-5b-cholestan-3-one (9a)
Jones reagent (0.6 mL) was added gradually to a stirred solution
of the 3-hydroxy-7,12-diacetate 8a (300 mg, 0.59 mmol) in ace-
tone (8 mL) and CH2Cl2 (1.5 mL) until the solution became dark
brown. After stirring at 0 C for 30 min, 2-propanol (0.8 mL) was
added to the mixture. The reaction product was extracted with
CH2Cl2. The combined extract was washed with water, dried over
Drierite, and evaporated to afford the 3-oxo-7,12-diacetate 9a
which crystallized from EtOAc as colorless needles; yield, 248 mg
(83%); mp, 171–172 C. 1H-NMR (500 MHz, CDCl3): d = 0.77 (s,
3H, 18-H3), 0.82 (d, 3H, J = 5.4 Hz, 21-H3), 0.86 (d, 6H, J = 5.4 Hz,
26-H3 and 27-H3), 1.02 (s, 3H, 19-H3), 2.07, 2.12 (each s, 3H,
OCOCH3), 5.00 (brs, 1H, 7b-H), 5.15 (brs, 1H, 12b-H). 13C-NMR
(125.8 MHz, CDCl3): d = 12.2 (C-18), 17.8 (C-21), 21.3, 21.5 (each
OCOCH3), 21.6 (C-19), 22.5 (C-26), 22.8 (C-27), 23.8 (C-15 and C-
23), 25.8 (C-11), 27.2 (C-16), 27.9 (C-25), 29.8 (C-9), 30.9 (C-6),
34.4 (C-10), 35.0 (C-20), 35.9 (C-22), 36.1 (C-1), 36.6 (C-2), 37.7
(C-8), 39.3 (C-24), 42.4 (C-5), 43.2 (C-14), 44.6 (C-4), 45.0 (C-13),
47.8 (C-17), 70.6 (C-7), 75.3 (C-12), 170.4, 170.5 (each OCOCH3),
212.4 (C-3). HR-APCI-MS, calcd. for C31H51O5 [M + H]+, 503.3737;
found, 503.3701.
3.3.13. 7a-Acetoxy-5b-cholestan-3-one (9b)
The 3-hydroxy-7-acetate 8b (400 mg, 0.90 mmol), subjected to
the oxidation reaction with Jones reagent and processed as de-
scribed for the preparation of 9a, afforded a homogeneous oily
product of the 3-oxo-7-acetate 9b, which resisted crystallization
attempts; yield, 372 mg (93%). 1H-NMR (500 MHz, CDCl3):
d = 0.68 (s, 3H, 18-H3), 0.87 (d, 6H, J = 6.8 Hz, 26-H3 and 27-H3),
0.92 (d, 3H, J = 5.0 Hz, 21-H3), 1.04 (s, 3H, 19-H3), 2.04 (s, 3H,
OCOCH3), 4.96 (brs, 1H, 7b-H). 13C-NMR (125.8 MHz, CDCl3):
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19), 22.5 (C-26), 22.8 (C-27), 23.6 (C-23), 23.8 (C-15), 28.0 (C-16),
28.1 (C-25), 31.0 (C-6), 34.9 (C-9) 35.0 (C-10), 35.7 (C-20), 36.1
(C-22), 36.6 (C-2), 36.9 (C-1), 37.9 (C-8), 39.4 (C-12 and C-24),
42.6 (C-5), 42.7 (C-13), 44.7 (C-4), 50.3 (C-14), 56.1 (C-17), 71.2
(C-7), 170.3 (OCOCH3), 212.6 (C-3). HR-APCI-MS, calcd. for
C29H49O3 [M + H]+, 445.3682; found, 445.3680.3.3.14. 7a,12a-Dihydroxy-5b-cholestan-3-one (10a)
The 3-oxo-7,12-diacetate 9a (200 mg, 0.40 mmol) was com-
pletely hydrolyzed in 10% methanolic KOH (3.5 g) at 30 C for
16 h. Most of the solvent was evaporated off, and the residue
was dissolved in water and acidiﬁed with 10% HCl with stirring
and ice-bath cooling. The precipitate was collected by ﬁltration
and washed with water. Recrystallization from methanol gave
the 7,12-dihydroxy-3-one 10a as colorless thin plates; yield,
149 mg (90%); mp, 195–197 C (literature value: mp, 209–210 C)
[21]. 1H-NMR (500 MHz, CDCl3): d = 0.74 (s, 3H, 18-H3), 0.86 (d,
3H, J = 6.0 Hz, 27-H3), 0.87 (d, 3H, J = 6.0 Hz, 26-H3), 0.98 (d, 3H,
J = 6.5 Hz, 21-H3), 1.00 (s, 3H, 19-H3), 3.93 (brs, 1H, 7b-H), 4.06
(brs, 1H, 12b-H). 13C-NMR (125.8 MHz, CDCl3): d = 12.6 (C-18),
17.8 (C-21), 21.7 (C-19), 22.5 (C-26), 22.8 (C-27), 23.1 (C-23),
23.8 (C-15), 27.3 (C-9), 27.5 (C-16), 28.0 (C-25), 28.5 (C-11), 33.7
(C-6), 34.9 (C-10), 35.4 (C-20), 36.0 (C-22), 36.6 (C-1), 36.8 (C-2),
39.4 (C-24), 39.6 (C-8), 41.9 (C-14), 43.1 (C-5), 45.6 (C-4), 46.6
(C-13), 47.7 (C-17), 68.3 (C-7), 72.9 (C-12), 213.1 (C-3). HR-APCI-
MS, calcd. for C27H45O3 [MH], 417.3369; found, 417.3361.3.3.15. 7a-Hydroxy-5b-cholestan-3-one (10b)
The 3-oxo-7-acetate 9b (300 mg, 0.67 mmol), subjected to com-
plete hydrolysis with 10% methanolic KOH (6 g) at 30 C for 16 h
and processed as described above, afforded the 7-hydroxy-3-one
10b; yield, 266 mg (98%); mp, 62–65 C (colorless needles from
petroleum ether) (literature value: mp, 122–123 C) [22]. 1H-
NMR (500 MHz, CDCl3): d = 0.70 (s, 3H, 18-H3), 0.87 (d, 6H,
J = 5.4 Hz, 26-H3 and 27-H3), 0.93 (d, 3H, J = 5.4 Hz, 21-H3), 1.01
(s, 3H, 19-H3), 3.93 (brs, 1H, 7b-H). 13C-NMR (125.8 MHz, CDCl3):
d = 11.8 (C-18), 18.7 (C-21), 21.0 (C-11), 21.9 (C-19), 22.6 (C-26),
22.8 (C-27), 23.7 (C-23), 23.8 (C-15), 28.0 (C-25), 28.2 (C-16),
33.4 (C-9), 33.8 (C-6), 35.3 (C-10), 35.8 (C-20), 36.2 (C-22), 36.8
(C-1), 37.0 (C-2), 39.4 (C-8), 39.5 (C-12), 39.6 (C-24), 42.7 (C-13),
43.2 (C-5), 45.6 (C-4), 50.4 (C-14), 56.2 (C-17), 68.6 (C-7), 213.2
(C-3). HR-ESI-MS, calcd. for C27H45O2 [MH], 401.3420; found
401.3434.3.3.16. 7a,12a-Diformyloxy-5b-cholestan-3-one (11a)
A solution of the 7,12-dihydroxy-3-one 10a (200 mg,
0.48 mmol) in 98% formic acid (2 mL) containing one drop of 60%
perchloric acid was stirred at room temperature for 1 h. Acetic
anhydride (2 mL) was added slowly with ice-bath cooling, and
then the mixture was poured into ice. The precipitated solid was
ﬁltered, washed with water, and the product (11a) was recrystal-
lized from methanol 11a as colorless thin plates; yield, 218 mg
(96%); mp, 176–178 C. 1H-NMR (500 MHz, CDCl3): d = 0.79 (s,
3H, 18-H3), 0.86 (d, 9H, J = 6.5 Hz, 21-H3 and 26-H3 and 27-H3),
1.04 (s, 3H, 19-H3), 5.16 (brs, 1H, 7b-H), 5.32 (brs, 1H, 12b-H),
8.10, 8.16 (each s, 1H, OCHO). 13C-NMR (125.8 MHz, CDCl3):
d = 12.2 (C-18), 17.8 (C-21), 21.6 (C-19), 22.5 (C-26), 22.8 (C-15
and C-27), 23.7 (C-23), 25.9 (C-11), 27.2 (C-16), 27.9 (C-25), 29.5
(C-9), 31.0 (C-6), 34.4 (C-10), 35.2 (C-20), 35.8 (C-22), 36.1 (C-1),
36.5 (C-2), 37.7 (C-8), 39.4 (C-24), 42.2 (C-5), 42.8 (C-14), 44.6
(C-4), 45.0 (C-13), 47.5 (C-17), 70.6 (C-7), 75.3 (C-12), 160.3,
160.5 (each OCHO), 211.7 (C-3). HR-APCI-MS, calcd for C29H47O5
[M + H]+, 475.3424; found 475.3458.3.3.17. 7a-Formyloxy-5b-cholestan-3-one (11b)
The 7-hydroxy-3-one 10b (250 mg, 0.62 mmol) was converted
to the 3-oxo-7-formate 11b by the method described for the prep-
aration of 11a. Although this compound was analytically pure by
TLC, and NMR, it resisted crystallization attempts; yield, 182 mg
(68%). 1H-NMR (500 MHz, CDCl3): d = 0.69 (s, 3H, 18-H3), 0.86 (d,
3H, J = 6.0 Hz, 27-H3), 0.87 (d, 3H, J = 6.0 Hz, 26-H3), 0.92 (d, 3H,
J = 6.6 Hz, 21-H3), 1.04 (s, 3H, 19-H3), 5.12 (brs, 1H, 7b-H) 8.06 (s,
1H, OCHO). 13C-NMR (125.8 MHz, CDCl3): d = 11.7 (C-18), 18.7
(C-21), 21.0 (C-11), 21.8 (C-19), 22.5 (C-26), 22.8 (C-27), 23.5 (C-
23), 23.7 (C-15), 28.0 (C-25), 28.1 (C-16), 31.2 (C-6), 34.8 (C-9),
35.0 (C-10), 35.7 (C-20), 36.1 (C-22), 36.5 (C-1), 36.8 (C-2), 37.9
(C-8), 39.4 (C-12 and C-24), 42.6 (C-5), 42.7 (C-13), 44.7 (C-4),
50.0 (C-14), 56.0 (C-17), 71.3 (C-7), 160.5 (OCHO), 212.1 (C-3).
HR-APCI-MS, calcd. for C28H47O3 [M + H]+, 431.3525; found
431.3545.
3.3.18. 7a,12a-Diformyloxy-4-cholesten-3-one (12a)
To a magnetically stirred solution of the 3-oxo-7,12-diformate
11a (50 mg, 0.11 mmol) in DMSO (5 mL) was added freshly pre-
pared IBX (40 mg, 0.28 mmol) and two drops of triﬂuoroacetic
acid; the mixture was stirred at 40 C for 40 h. After cooling to
room temperature, the reaction product was extracted with EtOAc,
and the combined extract was washed with saturated brine, dried
over Drierite, and evaporated to dryness. The crude product was
puriﬁed on a silica gel column (3 g). Elution with EtOAc-hexane
(1:4, v/v) yielded the conjugated 3-oxo-D4-7,12-diformate 12a
which was recrystallized from methanol as colorless prisms; yield,
28 mg (56%); mp, 134–136 C. 1H-NMR (500 MHz, CDCl3): d = 0.81
(s, 3H, 18-H3), 0.86 (d, 9H, J = 6.5 Hz, 21-H3 and 26-H3 and 27-H3),
1.21 (s, 3H, 19-H3), 5.19 (brs, 1H, 7b-H), 5.30 (brs, 1H, 12b-H), 5.71
(s, 1H, 4-H), 8.08, 8.11 (each s, 1H, OCHO). 13C-NMR (125.8 MHz,
CDCl3): d = 12.1 (C-18), 16.8 (C-19), 17.8 (C-21), 22.5 (C-26), 22.8
(C-15 and C-27), 23.7 (C-23), 25.6 (C-11), 27.1 (C-16), 27.9 (C-
25), 33.7 (C-2), 35.1 (C-1), 35.2 (C-20), 35.8 (C-22), 37.3 (C-6),
37.6 (C-10), 38.2 (C-9), 39.4 (C-24), 40.6 (C-8), 42.8 (C-14), 44.8
(C-13), 47.4 (C-17), 70.6 (C-7), 74.8 (C-12), 126.8 (C-4), 160.3,
160.4 (each OCHO), 165.0 (C-5), 198.4 (C-3). HR-APCI-MS, calcd.
for C29H45O5 [M + H]+, 473.3267; found 473.3307.
3.3.19. 7a-Formyloxy-4-cholesten-3-one (12b)
The 3-oxo-7-formate 11b (200 mg, 0.46 mmol), subjected to the
dehydration with IBX and processed as described for the prepara-
tion of 12a, afforded an oily residue. Chromatography of the oily
product on a silica gel column (10 g) and elution with EtOAc-hex-
ane (1:9, v/v) gave the conjugated 3-oxo-D4-7-formate 12b which
recrystallized from acetone as colorless thin plates; yield, 127 mg
(64%); mp, 152–155 C. 1H-NMR (500 MHz, CDCl3): d = 0.71 (s,
3H, 18-H3), 0.87 (d, 6H, J = 6.8 Hz, 26-H3 and 27-H3), 0.92 (d, 3H,
J = 5.0 Hz, 21-H3), 1.22 (s, 3H, 19-H3), 5.17 (brs, 1H, 7b-H) 5.70 (s,
1H, 4-H), 8.05 (s, 1H, OCHO). 13C-NMR (125.8 MHz, CDCl3):
d = 11.7 (C-18), 17.1 (C-19), 18.6 (C-21), 20.8 (C-11), 22.5 (C-26),
22.8 (C-27), 23.5 (C-23), 23.7 (C-15), 28.0 (C-16 and C-25), 33.9
(C-2), 35.4 (C-1), 35.6 (C-20), 36.0 (C-22), 37.4 (C-6), 38.2 (C-10),
38.3 (C-8), 39.0 (C-12), 39.4 (C-24), 42.4 (C-13), 46.2 (C-9), 50.0
(C-14), 55.9 (C-17), 71.2 (C-7), 126.5 (C-4), 160.4 (OCHO), 166.1
(C-5), 198.8 (C-3). HR-APCI-MS, calcd. for C28H45O3 [M + H]+,
429.3369; found 429.3411.
3.3.20. 7a,12a-Dihydroxy-4-cholesten-3-one (1a)
A solution of the 3-oxo-D4-7,12-diformate 12a (15 mg,
32 lmol) in THF (1 mL) and 0.8% aqueous NaOH (1 mL) was left
to stand at room temperature for 30 min; the reaction was moni-
tored by TLC. The solution was diluted with water, acidiﬁed by
10% HCl with ice-bath cooling, and the precipitated solid was col-
lected by ﬁltration, washed with water. Recrystallization from
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as colorless needles; yield, 11 mg (80%); mp, 147–148 C. 1H-NMR
(500 MHz, CDCl3): d = 0.75 (s, 3H, 18-H3), 0.86 (d, 3H, J = 6.8 Hz, 27-
H3), 0.87 (d, 3H, J = 6.8 Hz, 26-H3), 0.98 (d, 3H, J = 6.0 Hz, 21-H3),
1.19 (s, 3H, 19-H3), 3.98 (brs, 1H, 7b-H), 4.05 (brs, 1H, 12b-H),
5.82 (s, 1H, 4-H). 13C-NMR (125.8 MHz, CDCl3): d = 12.6 (C-18),
16.9 (C-19), 17.8 (C-21), 22.5 (C-26), 22.8 (C-27), 23.0 (C-15),
23.8 (C-23), 27.4 (C-16), 28.0 (C-25), 28.3 (C-11), 33.9 (C-2), 35.2
(C-1), 35.4 (C-20), 36.0 (C-22), 38.0 (C-10), 38.9 (C-9), 39.5 (C-
24), 40.0 (C-8), 40.8 (C-6), 42.0 (C-14), 46.4 (C-13), 47.6 (C-17),
68.3 (C-7), 72.5 (C-12), 126.9 (C-4), 167.4 (C-5), 198.7 (C-3). HR-
ESI-MS, calcd. for C27H43O3 [MH], 415.3212; found 415.3211.3.3.21. 7a-Hydroxy-4-cholesten-3-one (1b)
The 3-oxo-D4-diformate 12b (100 mg, 0.23 mmol) in THF
(5 mL) was hydrolyzed with 0.8% aqueous NaOH, followed by acid-
iﬁcation with 10% HCl as described for the preparation of 1a. After
being processed analogously, the crude product dissolved in ben-
zene was puriﬁed using a column of silica gel (5 g), and eluting
with EtOAc-hexane (3:7, v/v). Recrystallization from methanol
gave the 3-oxo-D4-7-hydroxy compound 1b as colorless needles;
yield, 73 mg (78%); mp, 180–182 C (literature value: mp, 183–
184 C) [23]. 1H-NMR (500 MHz, CDCl3): d = 0.71 (s, 3H, 18-H3),
0.89 (d, 3H, J = 6.8 Hz, 27-H3), 0.90 (d, 3H, J = 6.8 Hz, 26-H3), 0.91
(d, 3H, J = 5.4 Hz, 21-H3), 1.20 (s, 3H, 19-CH3), 3.97 (brs, 1H, 7b-
H), 5.80 (s, 1H, 4-H). 13C-NMR (125.8 MHz, CDCl3): d = 11.8 (C-
18), 17.0 (C-19), 18.6 (C-21), 20.8 (C-11), 22.5 (C-26), 22.8 (C-27),
23.5 (C-23), 23.7 (C-15), 28.0 (C-25), 28.1 (C-16), 33.9 (C-2), 35.3
(C-1), 35.7 (C-20), 36.0 (C-22), 38.4 (C-10), 39.1 (C-6), 39.4 (C-
24), 39.7 (C-8), 40.9 (C-12), 42.4 (C-13), 45.1 (C-9), 50.4 (C-14),
55.9 (C-17), 68.4 (C-7), 126.7 (C-4), 168.0 (C-5), 198.9 (C-3). HR-
ESI-MS, calcd. for C27H43O2 [MH], 399.3263; found 399.3280.3.4. X-ray crystal structure determination of 1b
Colorless crystals of 1b suitable for X-ray analysis were grown
by recrystallization from methanol. A crystal having dimensions
of 0.25  0.25  0.30 mm3 was selected. X-ray intensity data for
1b were collected on a Rigaku AFC-8 diffractometer equipped with
a Mercury CCD detector using monochromated Mo Ka radiation
(k = 0.71070 Å) at 193 K. The structure was solved using direct
methods and reﬁned by a full-matrix least-squares procedure
based on F2 using the Crystal Structure crystallographic software
package. The crystal structures were reﬁned with anisotropic tem-
perature factors for all non-hydrogen atoms. The positions of
hydrogen atoms were generated theoretically, and were reﬁned
using the riding model. Crystallographic details and atomic coordi-
nates are summarized in Tables 1 and 2, respectively.Acknowledgements
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